Two Midwest Companies Join Forces to Speed Development of Test to Identify Women at Risk for Preterm Birth

In a collaborative move to expand their diagnostic screening and testing portfolios, NxGen MDx, LLC., and NX Prenatal, Inc., announced a joint partnership to speed the development and deployment of a blood test to detect pregnancy biomarkers of preterm birth.

The partnership brings together NX Prenatal’s experience in developing exosome-associated biomarkers from maternal blood with NxGEN MDx’s comprehensive genetic screening solutions for women’s health applications.

Preterm birth affects 1 in 8 U.S. women and accounts for nearly half a million preterm births each year, costing families and insurers an estimated $26 billion. Globally, there are approximately 15 million preterm births annually, accounting for 75% of perinatal deaths. Preterm births are also a major cause of short and long-term medical complications in infants and children.

“We are excited to partner with the innovative NX Prenatal team. Our combined efforts are designed to identify which pregnant women are at risk for delivering prematurely as early as possible. NX Prenatal’s proven technology uniquely holds the potential to achieve this breakthrough,” says Alan Mack, CEO of NxGEN MDx.

Brian Brohman, Co-CEO of Nx Prenatal, concurs. “Our proprietary NeXosome Platform has the potential to identify women at risk for preterm birth as early as 10 weeks gestation — dramatically reducing the 22 weeks of current tests.”

“Clearly, our partnership aligns with our respective corporate missions. NX Prenatal’s new generation of diagnostics complements our current suite of tests that can help families and their physicians plan for healthy pregnancy outcomes,” adds Mack.

Identifying risk for preterm births earlier has a powerful ripple effect as well. “In addition to helping clinicians proactively manage those at greatest risk, patients and families will benefit from personalized care and potential tailored interventions, while payers and self-insured employers may ultimately enjoy lower claims costs related to preterm birth,” notes Gail Page, Executive Chair of NX Prenatal.

Financial terms of the transaction were not disclosed.

About NX Prenatal Inc.
NX Prenatal Inc. is a private U.S. based molecular diagnostics company located in Louisville, KY. NX Prenatal is developing diagnostic assays for adverse pregnancy outcomes and conditions such as preterm birth. The company has unlocked a new library of biomarkers for prenatal risk assessment as early as 10 weeks gestation. For more information, visit the company’s website at www.nxprenatal.com.

About NxGen MDx
NxGen MDx LLC is a leading clinical molecular diagnostics laboratory delivering highly accurate and precise genetic screening to detect genetic diseases or abnormalities to help guide family planning decisions for couples and their healthcare providers. Unlike other laboratories, NxGEN MDx’s technology examines the entire gene rather than parts of the gene, giving families a comprehensive assessment of their true risk. NxGen MDx is located in Grand Rapids, Michigan.